Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Engaging in the Recommended Amount of Physical Activity May Help Prevent 7 Cancer Types

January 7, 2020
By Hannah Slater
Article

Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.

According to a study published in the Journal of Clinical Oncology, engagement in the recommended amount of leisure-time physical activity (7.5-15 MET hours/week) was associated with lower risk for 7 different cancer types.1

While it has previously been known that physical activity is associated with a lower risk for several cancers, it was unclear if guideline recommended amounts of physical activity were associated with lower risk.2

“Physical activity guidelines have largely been based on their impact on chronic diseases like cardiovascular disease and diabetes,” Alpa Patel, PhD, senior scientific director of epidemiology research at the American Cancer Society, said in a press release. “These data provide strong support that these recommended levels are important to cancer prevention, as well.” 

In this cohort of 755,459 participants, individuals were followed for 10.1 years, and 50,620 incident cancers accrued during that time. Engagement in recommended amounts of activity were associated with a statistically significant lower risk for 7 of the 15 cancers studied, including colon (8%-14% lower risk in men), breast (6%-10% lower risk), endometrial (10%-18% lower risk), kidney (11%-17% lower risk), myeloma (14%-19% lower risk), liver (18%-27% lower risk), and non-Hodgkin lymphoma (11%-18% lower risk in women).

Both moderate- and vigorous-intensity activity seemed to be associated with lower risk for colon, breast, and kidney cancer, but the sample size for other cancer types was too limited to draw conclusive data. Adjustment for BMI eliminated the association with endometrial cancer but had a limited effect on other cancer types. 

Approximately half of the cancers associated with physical activity were found to have linear dose-response curves (colon, breast, endometrial, and head and neck cancer, as well as esophageal adenocarcinoma), with the lowest risk at levels well above the recommended minimum level of activity. For several cancers with a curvilinear association (kidney, gastric, and liver cancer), most of the risk reduction observed was associated with recommended amounts of physical activity. 

“This finding may explain in part previous observations that higher levels of activity were needed to achieve significantly lower risk of colon and breast cancer,” the authors wrote. “Given these linear associations, substantially lower relative risk estimates may have only been observable at higher activity levels in previous studies, particularly given smaller participant numbers and more limited statistical power in individual studies.” 

Additionally, the difference in the strength of associations for engaging in 7.5-15 MET hours/week when comparing results for breast cancer and liver cancer may reflect relevant differences in the underlying biologic mechanisms for distinct cancer types. These findings might indicate that there are fundamentally different physical activity dose-response relationships for all-cause and cardiovascular mortality and some cancers and sizable variation in the underlying biologic mechanisms that link physical activity to different types of cancer, however additional research is needed. 

Furthermore, researchers suggested that these findings provide actionable evidence for ongoing and future cancer prevention efforts, including the guidance that health care providers, fitness professionals, and public health practitioners should encourage adults to adopt and maintain physical activity at recommended levels.

References:

1. Matthews CE, Moore SC, Arem H, et al. Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk. Journal of Clinical Oncology. doi:10.1200/JCO.19.02407.

2. Report links recommended physical activity levels to lower risk of seven cancers [news release]. Published December 26, 2019. eurekalert.org/pub_releases/2019-12/acs-rlr122319.php. Accessed January 3, 2020.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content

Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.

Elranatamab Combo Yields Early Efficacy in Transplant-Ineligible NDMM

Russ Conroy
September 18th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 18th 2025
Podcast

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 18th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 18th 2025
Podcast

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 18th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 18th 2025
Article
Related Content

Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.

Elranatamab Combo Yields Early Efficacy in Transplant-Ineligible NDMM

Russ Conroy
September 18th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 18th 2025
Podcast

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 18th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 18th 2025
Podcast

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 18th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 18th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.